AASLD: Gilead wants to move the needle for fatty liver therapies

AASLD: Gilead wants to move the needle for fatty liver therapies

Source: 
Fierce Biotech
snippet: 

Gilead Sciences' nonalcoholic steatohepatitis (NASH) prospect selonsertib may have failed two phase 3 studies, but the company is putting the data from those studies to work. Part of that involves bringing better, noninvasive diagnostic tests to clinical trials, but also working to improve the current gold standard: invasive liver biopsy.